SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

JOURNAL DESCRIPTION

The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.

Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.

Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.

The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.

Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.

The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.

Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.

The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.

Medical Radiology and Radiation Safety. 2019. Vol. 64. No. 5. P. 58–68

DOI: 10.12737/1024-6177-2019-64-5-58-68

A.Y. Bushmanov, O.E. Klementyeva, A.A. Labushkina, A.V. Tultaev, V.N. Korsunskiy, O.V. Kuznetsova

Actual Problems and Perspectives of the Application of Nuclear Medicine Techniques in the Diagnostic and Treatment of Hepatocellular Carcinoma: Analytical Review

A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

A.Y. Bushmanov – First Deputy Director, Dr. Sci. Med., Prof.;
O.E. Klementyeva – Нead of Lab., PhD Biol.;
A.A. Labushkina – Research Worker, PhD Med.;
A.V. Tultaev – Senior Researcher, PhD Tech.;
V.N. Korsunskiy – Leading Researcher, Dr. Sci. Med., Prof.;
O.V. Kuznetsova – Vice-Rector, PhD Biol.

Abstract

In the presented review of publications, together with a brief analysis of the incidence, risk factors for the occurrence and methods of diagnosis of hepatocellular carcinoma (HCC), current problems and prospects for the application of nuclear medicine methods in the diagnosis and treatment of this disease are indicated. Hepatocellular carcinoma is one of the most common malignant tumors of the liver and is characterized by a rapidly progressing course with an unfavorable life expectancy. A variety of clinical manifestations of the disease creates certain difficulties in the early diagnosis of HCC. Although HCC screening is most commonly used to determine the level of alpha-fetoprotein (AFP), ultrasound (US), bolus CT and MRI, experience in the use of radionuclide imaging diagnostics, including positron emission tomography, is important in clinical practice (PET), which, not being the main method of primary diagnosis of HCC, however, confirmed their relevance in the differential diagnosis between a benign tumor and metastasis with unclear diagnostic data, as well as in the process of monitoring treatment and in the diagnosis of distant metastases. Conceptual issues in determining the treatment strategy of patients with HCC, depending on the staging of the disease, the prospects for optimizing treatment strategies and traditional methods of treating HCC in detail and in depth are covered in various publications, including publications of domestic authors. Based on this, the authors of the article limited themselves to a brief analysis of the use of embolization and radiation therapy methods for treating HCC, the active development of which in the last decade, as well as promising early results of treatment, suggest that radiation therapy can be considered as the main treatment method for HCC traditional methods.

Further study and development of radionuclide methods for the diagnosis and therapy of HCC, as well as the search and study of new radiopharmaceuticals for diagnosis and regional intraarterial radiotherapy is one of the promising directions in modern approaches to the diagnosis and treatment of HCC.

Key words: hepatocellular carcinoma, nuclear medicine, radioembolization, chemoembolization, lipiodol, sorafenib, intraarterial radionuclide therapy

REFERENCES

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA. Cancer J Clin. 2005;55:74-108.
  2. Sorinson SN. Viral hepatitis – St. Petersburg: Teza. 1998, 331 p. (in Russian).
  3. Patyutko Yu. I. Epidemiology, molecular biology and prevention of liver cancer. In: Surgical treatment of malignant liver tumors – Moscow: Practical medicine. 2005, 312 p. (in Russian).
  4. World Health Organization, Office of Health Communications and Public Relations. Cancer. In: WHO fact sheet, no 297. – Geneva: World Health Organization. 2006:4
  5. Bosch F.X, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterol. 2004:127(5, Suppl 1):5-16.
  6. Montalto G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002:963:13–20.
  7. Kurien T, Thyagarajan SP, Jeyaseelan L, et al. Community prevalence of hepatitis B infection and modes of transmission in Tamil Nadu, India. Indian J Med Res. 2005;121(5):670-5.
  8. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17.
  9. Lupberger J, Hildt E. Hepatitus B virus-induced oncogenesis. World J Gastroenterol. 2007;13(1):74-81.
  10. Breder VV, Bisovskaya YV. Hepatocellular carcinoma: the experience of the Russian Cancer Center. 4th International Scientific and Practical Conference «White Nights of Hepatology 2012». 2012. (in Russian).
  11. Ivashkin VT, Morozova MA, Maevskaya MV, et al. Risk factors for hepatocellular carcinoma. Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2009;1:4-15. (in Russian).
  12. Patutko YI, et al. Principles of early diagnosis and screening of HCC. The 2nd International Scientific and Practical Conference «White Nights of Hepatology 2010». 2010. (in Russian).
  13. Ivashkin VT, Pavlov ChS. Liver tumors, precancerous diseases and conditions. Hepatocellular carcinoma. Rational pharmacotherapy of diseases of the digestive system. – Moscow: Litterra. 2003, P. 459-64. (in Russian).
  14. Malignant neoplasms in Russia in 2013 (morbidity and mortality) Ed. A.D. Caprin, V.V. Starinskiy, G.V. Petrov.  Moscow. 2015, 250 p. (in Russian).
  15. Maev IV, Dicheva DT, Zhilyaev EV, et al. Difficulties in diagnosing hepatocellular carcinoma. Consilium Med. 2010;8:63-6. (in Russian).
  16. Trevisani F, D’Intino P.E, Morselli-Labate A.M, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatology. 2001, 34:570-5.
  17. Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817-26.
  18. Colli Al. Accurancy of ultrasonography, spiral CT, magnetic resonance and alpha-fetoprotein in diagnosing hepatocellular carcinoma; a systematic review. Am J Gastroenterol. 2006;101(3):513-23.
  19. Miller WJ, Federle MP, Campbell WL. Diagnosis and staging of hepatocellular carcinoma: comparison of CT and sonography in 36 liver transplantation patients. Am J Roentgenol. 1991;157:303-6.
  20. Lim JH, et al. Detection of hepatocellular carcinoma: value ofadding delayed phase to dual-phase helical CT. Am J Roentgenol. 2002;179(1):67-73.
  21. Burrel M, et al. MRI angiography in superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatol. 2003;38(4):1034-42.
  22. Radionuclide Diagnostics for Practical Doctors. Ed. YuB. Lishmanov, V.I. Chernov. Tomsk: STT. 2004. (in Russian).
  23. Khubutia MSh, Kudryashova NE, Sinyakova OG, et al. The use of radioisotope techniques of research in the preparation of patients for liver transplantation and in the postoperative period. Trasplantology. 2010;1:5-11. (in Russian).
  24. Jalmukashev UK, Tazhedinov IT. Quantitative evaluation of the results of two-indicator radionuclide studies in focal lesions of the liver. Medical Radiology and Radiation Safety. 2000;45(6):27-32. (in Russian).
  25. Smolyarchuk MYa, Davydov GA, Efimov ON. Radionuclide studies in the study of kidney function and diagnosis of metastatic skeletal lesions in oncourologic patients. – In the collection. “Materials of the 2nd All-Russian National Congress on Radiation Diagnostics and Therapy”, Moscow. 2008:268-9. (in Russian).
  26. Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133:510-6.
  27. Trufanov GE. Radiation diagnosis of liver diseases (MRI, CT, ultrasound, SPECT and PET). Moscow: GEOTAR-Media. 2008. 263 p. (in Russian).
  28. Khan MA, Combs CS, Brunt EM, et al. PET scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32:792-7.
  29. Saiton S, Koida I, Ikeda K, et al. Diagnosis and follow-up of small hepatocellular carcinoma with seledive intraarterial digital subtraction angiography. Hepatology. 1993;17:1003-7.
  30. Takayasu K, Moriyama N, Muramatsu Y, et al. The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients. Amer J Roentgenol. 1990;155:49-54.
  31. Tamm EP, Rabushka LS, Fishman EK, et al. Intrahepatic extramedullary hematopoiesis mimicking hemangioma on Tc-99m red blood cell SPECT examination. Clin Imag. 1995;19:88-91.
  32. Trends and practices in diagnosis and treatment of hepatocellular carcinoma. STI/PUB/1446. IAEA. 2010.
  33. Breder VV, Patyutko YuI, Peregudova MV, Kosyrev VYu, Kudashkin NE, Romanova KA, Laktionov KK. Comparative analysis of modern hepatocellular cancer staging systems – TNM / AJCC, CUPI, CLIP and BCLC in Russian oncology. Malignant Tumors. 2016:2:28-36. (in Russian).
  34. Breder VV, Laktionov KP. Hepatocellular carcinoma of the intermediate stage. BCLC B – official recommendations, as a basic treatment strategy and benchmark in assessing the effectiveness of new approaches. Malignant Tumors. 2016;4 (Special issue 1):29-35. (in Russian).
  35. Bazin IS, Breder VV, Virshke ER, Gorbunova VA, Dolgushin BI, Kosyrev VYu, et al. Clinical recommendations for diagnosis and treatment of patients with liver cancer and extrahepatic bile ducts. All-Russian Union of Public Associations Association of Russian Oncologists, Moscow. 2014. (in Russian).
  36. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol. 1998;29:129-34.
  37. Llovet JM, Real MI, Montana X, et al. Aterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9.
  38. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-71.
  39. Kasugai H, Kojima J, Tatsuta M, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intrarterial infusion of a mixture of cisplatin and ethodised oil. Gastroenterology. 1989, 97:965-71.
  40. Ben-Josef E, Normolle D, Pan C, et al. Phase II trial of high dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739-47.
  41. Park W, Lim do H, Paik S.W, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1143-50.
  42. Dionisi F, Amichetti M. Proton Therapy Results in the Treatment of Hepatocellular Carcinoma According to the Barcelona-Clinic Liver Cancer (BCLC) Staging System. Int J Med Phys, Clin Eng  Radiat Oncol. 2015;4:96-103.
  43. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of longterm outcomes. Gastroenterol. 2010;138:52-64.
  44. Sangro B, D’Avola D, Inarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opin Pharmacother. 2011;12:1057-73.
  45. Сoldwell D, Sangro B, Wasan H, Salem R, Kennedy A. General selection criteria of patients for radioembolization of liver tumors: an International Working Group report. Am J Clin Oncol. 2011;34:337-41.
  46. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with 90Y microspheres: Angiographic and technical consid erations. Cardiovasc Intervent Radiol. 2007;30(4):571-92.
  47. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: A state-of-the-art brachyterapy treatment foe primary and secondary liver malignancies: Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251.
  48. Drozdovskiy BYa, Petriev VM, Raziev PA, Goncharova AYa. Intraarterial selective therapy with cytostatic drugs and radiopharmaceuticals in malignant neoplasms (review). Oncology Issues. 1992;38(7):771-7. (in Russian).
  49. Petriev VM, Smoryzanova OA, Skvortsov VG, et al. Pharmacokinetic characteristics of the radiopharmaceutical 188Re-albumin microspheres after intravenous administration to laboratory animals. Chem Pharm J. 2013;47(11):3-6.
  50. Nakakuma K, Tashiro S, Uemura K, et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated hepatic artery for hepatic cancer. Nichidoku Iho. 1979;24:675-82.
  51. Ohishi H, Uchida H, Yoshimura H, et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology. 1985;154:25-9.
  52. Le Jeune JJ, Bourguet P, Victor G, et al. 131I-lipiodol in the treatment of hepatocellular carcinoma: results of a multicenter phase II study of fifty patients. Eur J Nucl Med. 1990;16:143.
  53. Raoul JL, Bourguet P, Bretagne JF, et al. Hepatic artery injection of 131I-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology. 1988. 168(2):541-5.
  54. Nakajo M, Kobayashi H, Shimabukuro K, et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med. 1988;29(6):1066-77.
  55. Raoul JI, Bretagne JF, Caucanas JP, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol. Cancer. 1992;69:346-52.
  56. Lambert B, Bacher K, Gemmel F, et al. 188Re-lipiodol for locoregional treatment of hepatocellular carcinoma: a phase I study. Eur J Nucl Med. 2003;30(suppl. 2):219.
  57. Bernal P, Osorio M, Gutierrez C, et al. Treatment of Liver Cancer with Rhenium-188 Lipiodol: Colombian Experience. Eur J Nucl Med. 2002;29(suppl. 1):180.
  58. Ruyck K De, Vral A, Lambert B, et al. Comparison of the cytotoxic effect of 131I-lipiodol therapy and 188Re-lipiodol therapy in hepatocellular cancer patients. Eur J Nucl Med. 2003;30(suppl. 2):343.
  59. Kennedy AS, Kleinstreuer C, Basciano CA, Dezarn WA. Computer modeling of yttrium-90 microsphere transport in the hepatic arterial tree to improve clinical outcomes. Int J Radiat Oncol Biol Phys. 2010;76:631-7.
  60. Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, et al. Patient selection and activity planning guide for selective internal radiotherapy with Yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2010;76:643-9.
  61. Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med. 2007;5:15.
  62. Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52:1741-9.
  63. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after 90Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: a European evaluation. Hepatology. 2011;54:868-78
  64. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94:1747-52.
  65. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90Y-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33:919-24.
  66. Furuse J, Ishii H, Nagase M, Kawashima M, Ogino T, Yoshino M. Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2005;20:1512-8.

For citation: Bushmanov AY, Klementyeva OE, Labushkina AA, Tultaev AV, Korsunskiy VN, Kuznetsova OV. Actual Problems and Perspectives of the Application of Nuclear Medicine Techniques in the Diagnostic and Treatment of Hepatocellular Carcinoma: Analytical Review. Medical Radiology and Radiation Safety. 2019;64(5):58-68. (in Russian).

DOI: 10.12737/1024-6177-2019-64-5-58-68

PDF (RUS) Full-text article (in Russian)

Contact Information

 

46, Zhivopisnaya st., 123098, Moscow, Russia Phone: +7 (499) 190-95-51. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal location

Attendance

2772627
Today
Yesterday
This week
Last week
This month
Last month
For all time
2354
3219
5573
25438
80370
75709
2772627
Forecast today
8376

Your IP:216.73.216.149
Visitor Counter

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх